LOGIN
DOWNLOAD
ESPAÑOL
RCT
ACE Report #6010
Oral ibandronic acid inferior to IV zoledronic acid for metastatic breast cancer to bone
How to Cite
OrthoEvidence. Oral ibandronic acid inferior to IV zoledronic acid for metastatic breast cancer to bone. ACE Report. 2014;3(4):65. Available from: https://myorthoevidence.com/AceReport/Report/6010
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial
Lancet Oncol. 2014 Jan;15(1):114-22. doi: 10.1016/S1470-2045(13)70539-4.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
1404 patients with bone metastases from breast cancer were randomized to receive treatment with either oral ibandronic acid or intravenous zoledronic acid. The frequency and timing of skeletal-related events (SREs) was the primary non-inferiority endpoint. After 96 weeks of treatment, 50 mg of oral ibandronic acid given daily was inferior to 4 mg of intravenous zoledronic acid given every 4 weeks ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.
LEARN MOREFor Reprints and Permissions, click here
Please Login or Join to leave comments.